Skip to content

Our latest paper in collaboration with Pfizer on the role of OCT2/MATE in creatinine clearance is accepted in JPET.

Peter Dines

Non-Executive Director

Peter Dines

Peter is the Chief Operating Officer of Mercia Asset Management, where he is responsible for a number of the life science portfolio investments including Newcells Biotech, Locate Bio, MyHealthChecked plc, Sense Biodetection, Axis Spine Technologies and Medovate.In July 2020 he oversaw the successful exit of The Native Antigen Company. Peter has been involved with a number of turnarounds and exits within the sector life science sector, including the acquisition of Surgicraft’s loss-making business where, as managing director, sales quadrupled within three years and the business was subsequently sold to a private equity backed business and Diagnostic World, a fast-growing diagnostic provider to the NHS.

Get our latest updates straight to your inbox